lbeveridge

Endothelial Cell News

PD-L1 Signaling Selectively Regulates T Cell Lymphatic Transendothelial Migration

[Nature Communications] Researchers showed that activated regulatory T cells and CD4 effector T cells used programmed death-1 (PD-1) and its ligand (PD-L1) and CD80/PD-L1, respectively, to regulate transendothelial migration across lymphatic endothelial cells.

Endothelial Cell News

Blood-Brain Barrier–Penetrating Single CRISPR-Cas9 Nanocapsules for Effective and Safe Glioblastoma Gene Therapy

[Science Advances] The authors designed a unique nanocapsule for efficient single CRISPR-Cas9 capsuling, noninvasive brain delivery and tumor cell targeting, demonstrating an effective and safe strategy for glioblastoma gene therapy.

Hematopoiesis News

Mitochondrial Oxidative Phosphorylation Is Dispensable for Survival of CD34+ Chronic Myeloid Leukemia Stem and Progenitor Cells

[Cell Death & Disease] Using label-free quantitative proteomic profiling, researchers compared the signature of CD34+ stem/progenitor cells collected from chronic myeloid leukemia individuals with that of healthy donors and observed significant changes in the abundance of enzymes associated with aerobic central carbonate metabolic pathways.

Hematopoiesis News

Adding Bendamustine to Melphalan before ASCT Improves CR Rate in Myeloma vs. Melphalan Alone: A Randomized Phase II Trial

[Bone Marrow Transplantation] Researchers compared standard 200 mg/m2 melphalan high-dose chemotherapy (HDCT) to experimental HDCT with 200 mg/m2 bendamustine, given both at days four and three, combined with 100 mg/m2 melphalan at days two and one before autologous stem cell transplantation (ASCT) as first-line consolidation in myeloma patients.

Hematopoiesis News

Artesunate Improves Venetoclax plus Cytarabine AML Cell Targeting by Regulating the Noxa/Bim/Mcl-1/P-Chk1 Axis

[Cell Death & Disease] The authors provided a new triple combination for AML treatment by targeting the Noxa/myeloid cell leukemia-1 (Mcl-1)/B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim) axis to reverse Mcl-1/p-checkpoint kinase 1 (Chk1) resistance of cytarabine therapy.

Intestinal Cell News

Processa Pharmaceuticals Doses First Patient in Amended Phase IB Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

[Processa Pharmaceuticals, Inc.] Processa Pharmaceuticals, Inc. announced that the first patient with advanced, refractory gastrointestinal cancer has been dosed in its amended maximum tolerated dose Phase IB trial for Next Generation Capecitabine.

1...870871872...904 Page 871 of 904

SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy

[Circulation Research] Pulmonary hypertension (PH) animal models were generated by treating mice/rats with chronic hypoxia for four weeks. SMYD2-vTg mice or wild-type rats and mice treated with LLY-507 were used to investigate the function of suppressor of variegation, enhancer of zeste, trithorax and myeloid Nervy DEAF-1 domain-containing protein 2 (SMYD2) on PH development in vivo.

PI3K/HSCB Axis Facilitates FOG1 Nuclear Translocation to Promote Erythropoiesis and Megakaryopoiesis

[eLife] Investigators identified heat shock cognate B as an indispensable protein for friend of GATA 1 (FOG1) nuclear translocation during erythropoiesis of K562 human erythroleukemia cells and cord-blood-derived human CD34+CD90+HSCs, as well as during megakaryopoiesis of the CD34+CD90+HSCs.

EVIDENCE Meta-Analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma

[Blood] This meta-analysis was based on the FDA guidance for considerations for a meta-analysis of minimal residual disease (MRD) as a clinical endpoint and evaluates MRD-negativity as an early endpoint reasonably likely to predict long-term clinical benefit.

All Articles by Author:

lbeveridge

Popular